Literature DB >> 18818401

Recurrent stroke and massive right-to-left shunt: results from the prospective Spanish multicenter (CODICIA) study.

Joaquín Serena1, Joan Marti-Fàbregas, Estevo Santamarina, Juan Jesús Rodríguez, María Jesús Perez-Ayuso, Jaime Masjuan, Tomás Segura, Jaime Gállego, Antonio Dávalos.   

Abstract

BACKGROUND AND
PURPOSE: Few studies have prospectively examined the risk of recurrent stroke associated with patent foramen ovale. We present the results of the Spanish right-to-left shunt (RLSh) multicenter study.
METHODS: Four hundred eighty-six patients with cryptogenic stoke were included at 17 participating hospitals. Patients were examined by contrast transcranial Doppler methods at baseline. The magnitude of RLSh was quantified during the Valsalva maneuver. Transthoracic and/or transesophageal echocardiography, computed tomography scan, or magnetic resonance imaging was performed. Functional outcome and stroke recurrence were evaluated at 3 months and yearly thereafter. The independent relation between RLSh magnitude and stroke recurrence was analyzed by logistic-regression analysis in the whole group and in the younger subgroup (<55 years).
RESULTS: Massive RLSh was detected in 200 patients (41.2%). The mean follow-up was 729+/-411 days. Stroke recurrence was low (5.8%, n=28) and similar in patients with massive RLSh, with nonmassive RLSh, and with no RLSh, in both the younger group (3.4% vs 2.3% vs 4.5%, respectively; P=0.75) and in the whole population (5.0% vs 6.2% vs 6.3%, respectively; P=0.58). Regression analysis found no association between massive RLSh and recurrent stroke in either group (in the whole population, odds ratio=0.94; 95% CI, 0.36 to 2.40; P=0.89; in the younger population, odds ratio=0.93; 95% CI, 0.18 to 4.91; P=0.93). These results were similar when concurrent atrial septal aneurysm and massive RLSh were analyzed and when antithrombotic treatment and concomitant stroke risk factors were included.
CONCLUSIONS: These results suggest that neither massive RLSh nor massive RLSh with concurrent atrial septal aneurysm is an independent risk factor for recurrent stroke, in either the general or younger stroke populations.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18818401     DOI: 10.1161/STROKEAHA.108.521427

Source DB:  PubMed          Journal:  Stroke        ISSN: 0039-2499            Impact factor:   7.914


  38 in total

1.  Patent foramen ovale and stroke: Should PFOs be closed in otherwise cryptogenic stroke?

Authors:  David A Carpenter; Andria L Ford; Jin-Moo Lee
Journal:  Curr Atheroscler Rep       Date:  2010-07       Impact factor: 5.113

Review 2.  Is patent foramen ovale a modifiable risk factor for stroke recurrence?

Authors:  David M Kent; David E Thaler
Journal:  Stroke       Date:  2010-10       Impact factor: 7.914

Review 3.  Update of secondary stroke prevention.

Authors:  Hans-Christoph Diener; Christian Weimar
Journal:  Nephrol Dial Transplant       Date:  2009-02-24       Impact factor: 5.992

Review 4.  Patent foramen ovale: anatomy, outcomes, and closure.

Authors:  Patrick A Calvert; Bushra S Rana; Anna C Kydd; Leonard M Shapiro
Journal:  Nat Rev Cardiol       Date:  2011-02-01       Impact factor: 32.419

5.  [Cardiac workup after cerebral ischemia. Consensus paper of the Working Group on Heart and Brain of the German Cardiac Society and German Stroke Society].

Authors:  U Laufs; U C Hoppe; S Rosenkranz; P Kirchhof; M Böhm; H-C Diener; M Endres; M Grond; W Hacke; T Meinertz; E B Ringelstein; J Röther; M Dichgans
Journal:  Nervenarzt       Date:  2010-04       Impact factor: 1.214

6.  The RoPE Score and Right-to-Left Shunt Severity by Transcranial Doppler in the CODICIA Study.

Authors:  Benjamin S Wessler; David M Kent; David E Thaler; Robin Ruthazer; Jennifer S Lutz; Joaquín Serena
Journal:  Cerebrovasc Dis       Date:  2015-07-11       Impact factor: 2.762

Review 7.  Stroke in younger patients: the heart of the matter.

Authors:  P E Cotter; M Belham; P J Martin
Journal:  J Neurol       Date:  2010-07-11       Impact factor: 4.849

8.  Endocardial Device Leads in Patients with Patent Foramen Ovale: Echocardiographic Correlates of Stroke/TIA and Mortality.

Authors:  Shiva P Ponamgi; Vaibhav R Vaidya; Christopher V Desimone; Amit Noheria; David O Hodge; Joshua P Slusser; Naser M Ammash; Charles J Bruce; Alejandro A Rabinstein; Paul A Friedman; Samuel J Asirvatham
Journal:  Pacing Clin Electrophysiol       Date:  2017-02-07       Impact factor: 1.976

Review 9.  Rethinking trial strategies for stroke and patent foramen ovale.

Authors:  David E Thaler; David M Kent
Journal:  Curr Opin Neurol       Date:  2010-02       Impact factor: 5.710

Review 10.  The brain's heart - therapeutic opportunities for patent foramen ovale (PFO) and neurovascular disease.

Authors:  Mingming Ning; Eng H Lo; Pei-Chen Ning; Su-Yu Xu; David McMullin; Zareh Demirjian; Ignacio Inglessis; G William Dec; Igor Palacios; Ferdinando S Buonanno
Journal:  Pharmacol Ther       Date:  2013-03-23       Impact factor: 12.310

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.